Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 200

1.

Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer.

Joshi K, Robert de Massy M, Ismail M, Reading JL, Uddin I, Woolston A, Hatipoglu E, Oakes T, Rosenthal R, Peacock T, Ronel T, Noursadeghi M, Turati V, Furness AJS, Georgiou A, Wong YNS, Ben Aissa A, Werner Sunderland M, Jamal-Hanjani M, Veeriah S, Birkbak NJ, Wilson GA, Hiley CT, Ghorani E, Guerra-Assunção JA, Herrero J, Enver T, Hadrup SR, Hackshaw A, Peggs KS, McGranahan N, Swanton C; TRACERx Consortium, Quezada SA, Chain B.

Nat Med. 2019 Oct 4. doi: 10.1038/s41591-019-0592-2. [Epub ahead of print]

PMID:
31591606
2.

Comparative analysis of melphalan versus busulphan T-cell deplete conditioning using alemtuzumab in unrelated donor stem cell transplantation for acute myeloid leukaemia.

Sellar RS, Mehra V, Fox TA, Grigg A, Kulasekararaj A, Sarma A, de Lavallade H, McLornan D, Raj K, Mufti GJ, Pagliuca A, Mackinnon S, Chakraverty R, Fielding AK, Carpenter B, Kottaridis PD, Khwaja A, Peggs KS, Thomson KJ, Morris EC, Potter VT.

Br J Haematol. 2019 Oct;187(1):e20-e24. doi: 10.1111/bjh.16136. Epub 2019 Aug 8. No abstract available.

PMID:
31396948
3.

Toxoplasmosis initially presenting as neurological sequelae of chimeric antigen receptor T-cell therapy.

Marzolini MAV, Jaunmuktane Z, Roddie C, O'Reilly M, Chiodini P, Peggs KS.

Lancet Infect Dis. 2019 Jul;19(7):788. doi: 10.1016/S1473-3099(19)30119-7. No abstract available.

PMID:
31250826
4.

Current Practice in Vitamin D Management in Allogeneic Hematopoietic Stem Cell Transplantation: A Survey by the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation.

Ros-Soto J, Snowden JA, Salooja N, Gilleece M, Parker A, Greenfield DM, Anthias C, Alfred A, Harrington A, Peczynski C, Peggs K, Madrigal A, Basak GW, Schoemans H; Transplant Complications Working Party of the EBMT.

Biol Blood Marrow Transplant. 2019 Oct;25(10):2079-2085. doi: 10.1016/j.bbmt.2019.06.015. Epub 2019 Jun 21.

PMID:
31229642
5.

In vitro comparison of currently available and investigational antiviral agents against pathogenic human double-stranded DNA viruses: A systematic literature review.

Chemaly RF, Hill JA, Voigt S, Peggs KS.

Antiviral Res. 2019 Mar;163:50-58. doi: 10.1016/j.antiviral.2019.01.008. Epub 2019 Jan 21. Review.

6.

ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.

Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, Maus MV, Park JH, Mead E, Pavletic S, Go WY, Eldjerou L, Gardner RA, Frey N, Curran KJ, Peggs K, Pasquini M, DiPersio JF, van den Brink MRM, Komanduri KV, Grupp SA, Neelapu SS.

Biol Blood Marrow Transplant. 2019 Apr;25(4):625-638. doi: 10.1016/j.bbmt.2018.12.758. Epub 2018 Dec 25. Review.

7.

Allogeneic stem cell transplantation as part of front line therapy for Mantle cell lymphoma.

Rule S, Cook G, Russell NH, Hunter A, Robinson S, Morley N, Sureda A, Patrick P, Clifton-Hadley L, Adedayo T, Kirkwood A, Peggs KS.

Br J Haematol. 2019 Mar;184(6):999-1005. doi: 10.1111/bjh.15723. Epub 2018 Dec 17.

PMID:
30560573
8.

A comparison of viral microneutralization and haemagglutination inhibition assays as measures of seasonal inactivated influenza vaccine immunogenicity in the first year after reduced intensity conditioning, lymphocyte depleted allogeneic haematopoietic stem cell transplant.

Miller PDE, de Silva TI, Leonard H, Anthias C, Hoschler K, Goddard K, Peggs K, Madrigal A, Snowden JA.

Vaccine. 2019 Jan 14;37(3):452-457. doi: 10.1016/j.vaccine.2018.11.061. Epub 2018 Dec 13.

PMID:
30554797
9.

Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party.

Bazarbachi A, Boumendil A, Finel H, Mohty M, Castagna L, Blaise D, Peggs KS, Afanasyev B, Diez-Martin JL, Corradini P, Michonneau D, Robinson S, Gutiérrez García G, Bonifazi F, Yakoub-Agha I, Gülbas Z, Bloor A, Delage J, Esquirol A, Malladi R, Scheid C, El-Cheikh J, Ghesquières H, Montoto S, Dreger P, Sureda A.

Cancer. 2019 Jan 1;125(1):90-98. doi: 10.1002/cncr.31755. Epub 2018 Oct 23.

10.

Lost in Translation: Deciphering the Mechanism of Action of Anti-human CTLA-4.

Quezada SA, Peggs KS.

Clin Cancer Res. 2019 Feb 15;25(4):1130-1132. doi: 10.1158/1078-0432.CCR-18-2509. Epub 2018 Oct 5.

PMID:
30291135
11.

Urine-derived lymphocytes as a non-invasive measure of the bladder tumor immune microenvironment.

Wong YNS, Joshi K, Khetrapal P, Ismail M, Reading JL, Sunderland MW, Georgiou A, Furness AJS, Ben Aissa A, Ghorani E, Oakes T, Uddin I, Tan WS, Feber A, McGovern U, Swanton C, Freeman A, Marafioti T, Briggs TP, Kelly JD, Powles T, Peggs KS, Chain BM, Linch MD, Quezada SA.

J Exp Med. 2018 Nov 5;215(11):2748-2759. doi: 10.1084/jem.20181003. Epub 2018 Sep 26.

12.

Sociodemographic and psychological determinants of influenza vaccine intention among recipients of autologous and allogeneic haematopoietic stem cell transplant: a cross-sectional survey of UK transplant recipients using a modified health belief model.

Miller PDE, Forster AS, de Silva TI, Leonard H, Anthias C, Mayhew M, Klammer M, Paskar S, Hurst E, Peggs K, Madrigal A, Snowden JA.

BMJ Open. 2018 Aug 8;8(8):e021222. doi: 10.1136/bmjopen-2017-021222.

13.

Successful translation and future prospects of TALEN editing for leukemia patients.

Werner Sunderland M, Peggs KS.

Expert Opin Biol Ther. 2018 Jul;18(7):725-726. doi: 10.1080/14712598.2018.1484105. Epub 2018 Jun 14. No abstract available.

PMID:
29860877
14.

The function and dysfunction of memory CD8+ T cells in tumor immunity.

Reading JL, Gálvez-Cancino F, Swanton C, Lladser A, Peggs KS, Quezada SA.

Immunol Rev. 2018 May;283(1):194-212. doi: 10.1111/imr.12657. Review.

PMID:
29664561
15.

Should all patients with Hodgkin lymphoma who relapse after autologous SCT be considered for allogeneic SCT?

Peggs KS.

Blood Adv. 2018 Apr 10;2(7):817-820. doi: 10.1182/bloodadvances.2017011122. Review. No abstract available.

16.

Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies.

Arce Vargas F, Furness AJS, Litchfield K, Joshi K, Rosenthal R, Ghorani E, Solomon I, Lesko MH, Ruef N, Roddie C, Henry JY, Spain L, Ben Aissa A, Georgiou A, Wong YNS, Smith M, Strauss D, Hayes A, Nicol D, O'Brien T, Mårtensson L, Ljungars A, Teige I, Frendéus B; TRACERx Melanoma; TRACERx Renal; TRACERx Lung consortia, Pule M, Marafioti T, Gore M, Larkin J, Turajlic S, Swanton C, Peggs KS, Quezada SA.

Cancer Cell. 2018 Apr 9;33(4):649-663.e4. doi: 10.1016/j.ccell.2018.02.010. Epub 2018 Mar 22.

17.

Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party.

Bazarbachi A, Boumendil A, Finel H, Mohty M, Castagna L, Peggs KS, Blaise D, Afanasyev B, Diez-Martin JL, Sierra J, Bloor A, Martinez C, Robinson S, Malladi R, El-Cheikh J, Corradini P, Montoto S, Dreger P, Sureda A.

Br J Haematol. 2018 Apr;181(1):86-96. doi: 10.1111/bjh.15152. Epub 2018 Feb 22.

PMID:
29468647
18.

Differential binding affinity of mutated peptides for MHC class I is a predictor of survival in advanced lung cancer and melanoma.

Ghorani E, Rosenthal R, McGranahan N, Reading JL, Lynch M, Peggs KS, Swanton C, Quezada SA.

Ann Oncol. 2018 Jan 1;29(1):271-279. doi: 10.1093/annonc/mdx687.

19.

Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT Lymphoma Working Party.

Robinson SP, Boumendil A, Finel H, Peggs KS, Chevallier P, Sierra J, Finke J, Poiré X, Maillard N, Milpied N, Yakoub-Agha I, Koh M, Kröger N, Nagler A, Koc Y, Dietrich S, Montoto S, Dreger P.

Bone Marrow Transplant. 2018 May;53(5):617-624. doi: 10.1038/s41409-017-0067-3. Epub 2018 Jan 15.

PMID:
29335632
20.

Successful outcome following allogeneic hematopoietic stem cell transplantation in adults with primary immunodeficiency.

Fox TA, Chakraverty R, Burns S, Carpenter B, Thomson K, Lowe D, Fielding A, Peggs K, Kottaridis P, Uttenthal B, Bigley V, Buckland M, Grandage V, Denovan S, Grace S, Dahlstrom J, Workman S, Symes A, Mackinnon S, Hough R, Morris E.

Blood. 2018 Feb 22;131(8):917-931. doi: 10.1182/blood-2017-09-807487. Epub 2017 Dec 26.

21.

Corrigendum: Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.

Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, Le Quesne J, Moore DA, Veeriah S, Rosenthal R, Marafioti T, Kirkizlar E, Watkins TBK, McGranahan N, Ward S, Martinson L, Riley J, Fraioli F, Al Bakir M, Grönroos E, Zambrana F, Endozo R, Bi WL, Fennessy FM, Sponer N, Johnson D, Laycock J, Shafi S, Czyzewska-Khan J, Rowan A, Chambers T, Matthews N, Turajlic S, Hiley C, Lee SM, Forster MD, Ahmad T, Falzon M, Borg E, Lawrence D, Hayward M, Kolvekar S, Panagiotopoulos N, Janes SM, Thakrar R, Ahmed A, Blackhall F, Summers Y, Hafez D, Naik A, Ganguly A, Kareht S, Shah R, Joseph L, Quinn AM, Crosbie PA, Naidu B, Middleton G, Langman G, Trotter S, Nicolson M, Remmen H, Kerr K, Chetty M, Gomersall L, Fennell DA, Nakas A, Rathinam S, Anand G, Khan S, Russell P, Ezhil V, Ismail B, Irvin-Sellers M, Prakash V, Lester JF, Kornaszewska M, Attanoos R, Adams H, Davies H, Oukrif D, Akarca AU, Hartley JA, Lowe HL, Lock S, Iles N, Bell H, Ngai Y, Elgar G, Szallasi Z, Schwarz RF, Herrero J, Stewart A, Quezada SA, Peggs KS, Van Loo P, Dive C, Lin CJ, Rabinowitz M, Aerts HJWL, Hackshaw A, Shaw JA, Zimmermann BG, Swanton C.

Nature. 2018 Feb 8;554(7691):264. doi: 10.1038/nature25161. Epub 2017 Dec 20.

PMID:
29258292
22.

Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies.

Maciocia PM, Wawrzyniecka PA, Philip B, Ricciardelli I, Akarca AU, Onuoha SC, Legut M, Cole DK, Sewell AK, Gritti G, Somja J, Piris MA, Peggs KS, Linch DC, Marafioti T, Pule MA.

Nat Med. 2017 Dec;23(12):1416-1423. doi: 10.1038/nm.4444. Epub 2017 Nov 13.

PMID:
29131157
23.

Results of a multicentre UK-wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive setting.

Eyre TA, Phillips EH, Linton KM, Arumainathan A, Kassam S, Gibb A, Allibone S, Radford J, Peggs K, Burton C, Stewart G, LeDieu R, Booth C, Osborne WL, Miall F, Eyre DW, Ardeshna KM, Collins GP.

Br J Haematol. 2017 Nov;179(3):471-479. doi: 10.1111/bjh.14898. Epub 2017 Aug 31. Erratum in: Br J Haematol. 2018 Jan;180(2):309.

PMID:
28857136
24.

Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation as Alternative to Matched Sibling or Unrelated Donor Transplantation for Hodgkin Lymphoma: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation.

Martínez C, Gayoso J, Canals C, Finel H, Peggs K, Dominietto A, Castagna L, Afanasyev B, Robinson S, Blaise D, Corradini P, Itälä-Remes M, Bermúdez A, Forcade E, Russo D, Potter M, McQuaker G, Yakoub-Agha I, Scheid C, Bloor A, Montoto S, Dreger P, Sureda A; Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

J Clin Oncol. 2017 Oct 20;35(30):3425-3432. doi: 10.1200/JCO.2017.72.6869. Epub 2017 Aug 28.

25.

Routine vaccination practice after adult and paediatric allogeneic haematopoietic stem cell transplant: a survey of UK NHS programmes.

Miller PDE, de Silva TI, Skinner R, Gilleece M, Peniket A, Hamblin A, Greenfield D, Anthias C, Peggs K, Madrigal A, Snowden JA.

Bone Marrow Transplant. 2017 Jul;52(7):1082. doi: 10.1038/bmt.2017.87.

PMID:
28677683
26.

The "Achilles' Heel" of Cancer and Its Implications for the Development of Novel Immunotherapeutic Strategies.

Joshi K, Chain BM, Peggs KS, Quezada SA.

Cold Spring Harb Perspect Med. 2018 Jan 2;8(1). pii: a027086. doi: 10.1101/cshperspect.a027086. Review.

PMID:
28630228
27.

Immunotherapy for transplantation-associated viral infections.

Roddie C, Peggs KS.

J Clin Invest. 2017 Jun 30;127(7):2513-2522. doi: 10.1172/JCI90599. Epub 2017 Jun 19. Review.

28.

Evolving adoptive cellular therapies in urological malignancies.

Wong YNS, Joshi K, Pule M, Peggs KS, Swanton C, Quezada SA, Linch M.

Lancet Oncol. 2017 Jun;18(6):e341-e353. doi: 10.1016/S1470-2045(17)30327-3. Review.

PMID:
28593860
29.

Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.

Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, Le Quesne J, Moore DA, Veeriah S, Rosenthal R, Marafioti T, Kirkizlar E, Watkins TBK, McGranahan N, Ward S, Martinson L, Riley J, Fraioli F, Al Bakir M, Grönroos E, Zambrana F, Endozo R, Bi WL, Fennessy FM, Sponer N, Johnson D, Laycock J, Shafi S, Czyzewska-Khan J, Rowan A, Chambers T, Matthews N, Turajlic S, Hiley C, Lee SM, Forster MD, Ahmad T, Falzon M, Borg E, Lawrence D, Hayward M, Kolvekar S, Panagiotopoulos N, Janes SM, Thakrar R, Ahmed A, Blackhall F, Summers Y, Hafez D, Naik A, Ganguly A, Kareht S, Shah R, Joseph L, Marie Quinn A, Crosbie PA, Naidu B, Middleton G, Langman G, Trotter S, Nicolson M, Remmen H, Kerr K, Chetty M, Gomersall L, Fennell DA, Nakas A, Rathinam S, Anand G, Khan S, Russell P, Ezhil V, Ismail B, Irvin-Sellers M, Prakash V, Lester JF, Kornaszewska M, Attanoos R, Adams H, Davies H, Oukrif D, Akarca AU, Hartley JA, Lowe HL, Lock S, Iles N, Bell H, Ngai Y, Elgar G, Szallasi Z, Schwarz RF, Herrero J, Stewart A, Quezada SA, Peggs KS, Van Loo P, Dive C, Lin CJ, Rabinowitz M, Aerts HJWL, Hackshaw A, Shaw JA, Zimmermann BG; TRACERx consortium; PEACE consortium, Swanton C.

Nature. 2017 Apr 26;545(7655):446-451. doi: 10.1038/nature22364. Erratum in: Nature. 2017 Dec 20;:.

30.

Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors.

Arce Vargas F, Furness AJS, Solomon I, Joshi K, Mekkaoui L, Lesko MH, Miranda Rota E, Dahan R, Georgiou A, Sledzinska A, Ben Aissa A, Franz D, Werner Sunderland M, Wong YNS, Henry JY, O'Brien T, Nicol D, Challacombe B, Beers SA; Melanoma TRACERx Consortium; Renal TRACERx Consortium; Lung TRACERx Consortium, Turajlic S, Gore M, Larkin J, Swanton C, Chester KA, Pule M, Ravetch JV, Marafioti T, Peggs KS, Quezada SA.

Immunity. 2017 Apr 18;46(4):577-586. doi: 10.1016/j.immuni.2017.03.013. Epub 2017 Apr 11.

31.

Impact of Alemtuzumab Scheduling on Graft-versus-Host Disease after Unrelated Donor Fludarabine and Melphalan Allografts.

Green K, Pearce K, Sellar RS, Jardine L, Nicolson PLR, Nagra S, Bigley V, Jackson G, Dickinson AM, Thomson K, Mackinnon S, Craddock C, Peggs KS, Collin M.

Biol Blood Marrow Transplant. 2017 May;23(5):805-812. doi: 10.1016/j.bbmt.2017.02.007. Epub 2017 Feb 14.

32.

Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells.

Qasim W, Zhan H, Samarasinghe S, Adams S, Amrolia P, Stafford S, Butler K, Rivat C, Wright G, Somana K, Ghorashian S, Pinner D, Ahsan G, Gilmour K, Lucchini G, Inglott S, Mifsud W, Chiesa R, Peggs KS, Chan L, Farzeneh F, Thrasher AJ, Vora A, Pule M, Veys P.

Sci Transl Med. 2017 Jan 25;9(374). pii: eaaj2013. doi: 10.1126/scitranslmed.aaj2013. Erratum in: Sci Transl Med. 2017 Feb 15;9(377):null.

PMID:
28123068
33.

Routine vaccination practice after adult and paediatric allogeneic haematopoietic stem cell transplant: a survey of UK NHS programmes.

Miller PDE, de Silva TI, Skinner R, Gilleece M, Peniket A, Hamblin A, Greenfield D, Anthias C, Peggs K, Madrigal A, Snowden JA.

Bone Marrow Transplant. 2017 May;52(5):775-777. doi: 10.1038/bmt.2016.362. Epub 2017 Jan 23. No abstract available. Erratum in: Bone Marrow Transplant. 2017 Jul;52(7):1082.

34.

Treatment pathways and resource use associated with recurrent Hodgkin lymphoma after autologous stem cell transplantation.

Radford J, McKay P, Malladi R, Johnson R, Bloor A, Percival F, Sureda A, Peggs KS.

Bone Marrow Transplant. 2017 Mar;52(3):452-454. doi: 10.1038/bmt.2016.244. Epub 2017 Jan 16. No abstract available.

35.

Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin's lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

Genadieva-Stavrik S, Boumendil A, Dreger P, Peggs K, Briones J, Corradini P, Bacigalupo A, Socié G, Bonifazi F, Finel H, Velardi A, Potter M, Bruno B, Castagna L, Malladi R, Russell N, Sureda A.

Ann Oncol. 2016 Dec;27(12):2251-2257. doi: 10.1093/annonc/mdw421. Epub 2016 Oct 24.

36.

Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS prodigy.

Mock U, Nickolay L, Philip B, Cheung GW, Zhan H, Johnston ICD, Kaiser AD, Peggs K, Pule M, Thrasher AJ, Qasim W.

Cytotherapy. 2016 Aug;18(8):1002-1011. doi: 10.1016/j.jcyt.2016.05.009.

PMID:
27378344
37.

Neoantigen heterogeneity: a key driver of immune response and sensitivity to immune checkpoint blockade?

Furness AJ, Quezada SA, Peggs KS.

Immunotherapy. 2016 Jun;8(7):763-6. doi: 10.2217/imt-2016-0064. No abstract available.

38.

A retrospective comparison of toxicity and initial efficacy of two autologous stem cell transplant conditioning regimens for relapsed lymphoma: LEAM and BEAM.

Kothari J, Foley M, Peggs KS, Mackenzie S, Thomson K, Morris E, Ardeshna KM, Virchis AE, Linch DC, Lambert J.

Bone Marrow Transplant. 2016 Oct;51(10):1397-1399. doi: 10.1038/bmt.2016.134. Epub 2016 May 23. No abstract available.

PMID:
27214072
39.

TALEN-Mediated Inactivation of PD-1 in Tumor-Reactive Lymphocytes Promotes Intratumoral T-cell Persistence and Rejection of Established Tumors.

Menger L, Sledzinska A, Bergerhoff K, Vargas FA, Smith J, Poirot L, Pule M, Hererro J, Peggs KS, Quezada SA.

Cancer Res. 2016 Apr 15;76(8):2087-93. doi: 10.1158/0008-5472.CAN-15-3352. Erratum in: Cancer Res. 2016 Oct 15;76(20):6130. Cancer Res. 2017 Jun 15;77(12 ):3379.

40.

Guidelines for the management of diffuse large B-cell lymphoma.

Chaganti S, Illidge T, Barrington S, Mckay P, Linton K, Cwynarski K, McMillan A, Davies A, Stern S, Peggs K; British Committee for Standards in Haematology.

Br J Haematol. 2016 Jul;174(1):43-56. doi: 10.1111/bjh.14136. Epub 2016 May 16. No abstract available.

PMID:
27196701
41.

Impact of Pretransplantation (18)F-Fluorodeoxyglucose-Positron Emission Tomography on Survival Outcomes after T Cell-Depleted Allogeneic Transplantation for Hodgkin Lymphoma.

Reyal Y, Kayani I, Bloor AJC, Fox CP, Chakraverty R, Sjursen AM, Fielding AK, Ben Taylor M, Bishton MJ, Morris EC, Thomson KJ, Russell N, Mackinnon S, Peggs KS.

Biol Blood Marrow Transplant. 2016 Jul;22(7):1234-1241. doi: 10.1016/j.bbmt.2016.03.034. Epub 2016 Apr 14.

42.

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade.

McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, Jamal-Hanjani M, Wilson GA, Birkbak NJ, Hiley CT, Watkins TB, Shafi S, Murugaesu N, Mitter R, Akarca AU, Linares J, Marafioti T, Henry JY, Van Allen EM, Miao D, Schilling B, Schadendorf D, Garraway LA, Makarov V, Rizvi NA, Snyder A, Hellmann MD, Merghoub T, Wolchok JD, Shukla SA, Wu CJ, Peggs KS, Chan TA, Hadrup SR, Quezada SA, Swanton C.

Science. 2016 Mar 25;351(6280):1463-9. doi: 10.1126/science.aaf1490. Epub 2016 Mar 3.

43.

A donor-specific epigenetic classifier for acute graft-versus-host disease severity in hematopoietic stem cell transplantation.

Paul DS, Jones A, Sellar RS, Mayor NP, Feber A, Webster AP, Afonso N, Sergeant R, Szydlo RM, Apperley JF, Widschwendter M, Mackinnon S, Marsh SG, Madrigal JA, Rakyan VK, Peggs KS, Beck S.

Genome Med. 2015 Dec 15;7:128. doi: 10.1186/s13073-015-0246-z.

44.

Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy.

Śledzińska A, Menger L, Bergerhoff K, Peggs KS, Quezada SA.

Mol Oncol. 2015 Dec;9(10):1936-65. doi: 10.1016/j.molonc.2015.10.008. Epub 2015 Oct 26. Review.

45.

Recommendations for a standard UK approach to incorporating umbilical cord blood into clinical transplantation practice: an update on cord blood unit selection, donor selection algorithms and conditioning protocols.

Hough R, Danby R, Russell N, Marks D, Veys P, Shaw B, Wynn R, Vora A, Mackinnon S, Peggs KS, Crawley C, Craddock C, Pagliuca A, Cook G, Snowden JA, Clark A, Marsh J, Querol S, Parkes G, Braund H, Rocha V.

Br J Haematol. 2016 Feb;172(3):360-70. doi: 10.1111/bjh.13802. Epub 2015 Nov 18.

PMID:
26577457
46.

TALEN-mediated genetic inactivation of the glucocorticoid receptor in cytomegalovirus-specific T cells.

Menger L, Gouble A, Marzolini MA, Pachnio A, Bergerhoff K, Henry JY, Smith J, Pule M, Moss P, Riddell SR, Quezada SA, Peggs KS.

Blood. 2015 Dec 24;126(26):2781-9. doi: 10.1182/blood-2015-08-664755. Epub 2015 Oct 27.

PMID:
26508783
47.

An Insufferable Business: Ethics, Nonhuman Animals and Biomedical Experiments.

Peggs K.

Animals (Basel). 2015 Jul 22;5(3):624-42. doi: 10.3390/ani5030376.

48.

Recent advances in antibody-based therapies for Hodgkin Lymphoma.

Peggs KS.

Br J Haematol. 2015 Oct;171(2):171-178. doi: 10.1111/bjh.13578. Epub 2015 Jul 17. Review.

PMID:
26184792
49.

Multiplex Genome-Edited T-cell Manufacturing Platform for "Off-the-Shelf" Adoptive T-cell Immunotherapies.

Poirot L, Philip B, Schiffer-Mannioui C, Le Clerre D, Chion-Sotinel I, Derniame S, Potrel P, Bas C, Lemaire L, Galetto R, Lebuhotel C, Eyquem J, Cheung GW, Duclert A, Gouble A, Arnould S, Peggs K, Pule M, Scharenberg AM, Smith J.

Cancer Res. 2015 Sep 15;75(18):3853-64. doi: 10.1158/0008-5472.CAN-14-3321. Epub 2015 Jul 16.

50.

Autologous stem cell transplantation outcomes in elderly patients with B cell Non-Hodgkin Lymphoma.

Gohil SH, Ardeshna KM, Lambert JM, Pule MA, Mohamedbhai S, Virchis A, Morris EC, Linch DC, Thomson KJ, Peggs KS.

Br J Haematol. 2015 Oct;171(2):197-204. doi: 10.1111/bjh.13561. Epub 2015 Jun 26.

PMID:
26119524

Supplemental Content

Support Center